These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26113579)

  • 1. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.
    Chen TT
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26113579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.
    Izar B; Regan MM; McDermott DF
    Cancer J; 2017; 23(1):63-67. PubMed ID: 28114257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy.
    Cully M
    Nat Rev Drug Discov; 2015 Jun; 14(6):374-5. PubMed ID: 26027531
    [No Abstract]   [Full Text] [Related]  

  • 4. Some statistical considerations in the clinical development of cancer immunotherapies.
    Huang B
    Pharm Stat; 2018 Feb; 17(1):49-60. PubMed ID: 29098766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.
    Mick R; Chen TT
    Cancer Immunol Res; 2015 Dec; 3(12):1292-8. PubMed ID: 26644449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.
    Lee L; Gupta M; Sahasranaman S
    J Clin Pharmacol; 2016 Feb; 56(2):157-69. PubMed ID: 26183909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
    Teng F; Kong L; Meng X; Yang J; Yu J
    Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
    Chen TT
    BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors: Basics and Challenges.
    Li B; Chan HL; Chen P
    Curr Med Chem; 2019; 26(17):3009-3025. PubMed ID: 28782469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?
    Chen TT
    Cancer Immunol Res; 2018 Mar; 6(3):250-254. PubMed ID: 31343973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint blockade immunotherapy for cancer comes of age.
    Brower V
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745014
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.
    Atkins MB; Larkin J
    J Natl Cancer Inst; 2016 Jun; 108(6):djv414. PubMed ID: 26839346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
    Koster BD; de Gruijl TD; van den Eertwegh AJ
    Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulation: checkpoint blockade etc.
    Curry WT; Lim M
    Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii26-vii31. PubMed ID: 26516223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved endpoints for cancer immunotherapy trials.
    Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
    J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.
    Francis DM; Thomas SN
    Adv Drug Deliv Rev; 2017 May; 114():33-42. PubMed ID: 28455187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic Overview of Current Immunotherapy Approaches in Cancer.
    Velcheti V; Schalper K
    Am Soc Clin Oncol Educ Book; 2016; 35():298-308. PubMed ID: 27249709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination Therapy of Immune Checkpoint Inhibitors].
    Kitano S
    Gan To Kagaku Ryoho; 2017 Sep; 44(9):727-732. PubMed ID: 28912397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SnapShot: Immune Checkpoint Inhibitors.
    Abril-Rodriguez G; Ribas A
    Cancer Cell; 2017 Jun; 31(6):848-848.e1. PubMed ID: 28609660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.